169 related articles for article (PubMed ID: 1579329)
1. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Soper JT; Berchuck A; Dodge R; Clarke-Pearson DL
Obstet Gynecol; 1992 Jun; 79(6):993-7. PubMed ID: 1579329
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Soper JT; Berchuck A; Clarke-Pearson DL
Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
[TBL] [Abstract][Full Text] [Related]
5. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
Bolis G; Colombo N; Pecorelli S; Torri V; Marsoni S; Bonazzi C; Chiari S; Favalli G; Mangili G; Presti M
Ann Oncol; 1995 Nov; 6(9):887-93. PubMed ID: 8624291
[TBL] [Abstract][Full Text] [Related]
7. [Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bolze PA; Collinet P; Golfier F; Bourgin C
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):168-179. PubMed ID: 30686727
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
9. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
10. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
11. Ovarian carcinoma: adjuvant treatment with P-32.
Reddy S; Sutton GP; Stehman FB; Hornback NB; Ehrlich CE
Radiology; 1987 Oct; 165(1):275-8. PubMed ID: 3628782
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma.
Soper JT; Creasman WT; Clarke-Pearson DL; Sullivan DC; Vergadoro F; Johnston WW
Am J Obstet Gynecol; 1985 Sep; 153(2):191-6. PubMed ID: 4037013
[TBL] [Abstract][Full Text] [Related]
14. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
15. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
16. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
Powell JL; Burrell MO; Kirchner AB
South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895
[TBL] [Abstract][Full Text] [Related]
18. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y
J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Powell JL; Kirchner AB
J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
[No Abstract] [Full Text] [Related]
20. Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma.
Raymond E; Drolet Y; Marpeau L; Louvet C; Cady J; Tessier C; Faivre S; Ouellet P; Lavoie A; Rioux E; de Gramont A; Krulik M
Eur J Obstet Gynecol Reprod Biol; 1997 Apr; 72(2):181-90. PubMed ID: 9134399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
